Zacks Investment Research
02 Mar 2026, 15:30 UTC · 30w ago
Verdict
Headline takes no side. We score XERS +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Xeris Biopharma reported a significant EPS surprise of 84.62%, with $0.06 compared to the $0.03 consensus estimate.
More positive than 93% of claims this week
Xeris Biopharma's quarterly revenue rose 42.8% year-over-year to $85.81 million, beating estimates by 5.38%.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 79% of claims this week
Xeris Biopharma shifted from a loss of -$0.03 per share a year ago to a profit of $0.06 per share in the quarter ended December 2025.
So whatThe transition to profitability is a key valuation milestone for biotech firms.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported strong year-over-year revenue and EPS growth, beating Zacks consensus estimates on both metrics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+57.5%
Price agrees with the score
$9.64 vs $6.12 close before publication (Feb 27) · not market-adjusted
XERS chart →